Last reviewed · How we verify

CardiolRx — Competitive Intelligence Brief

CardiolRx (CardiolRx) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Exosome therapy. Area: Cardiovascular.

phase 3 Exosome therapy Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

CardiolRx (CardiolRx) — Cardiol Therapeutics Inc.. CardiolRx is a cardiac-regenerative therapy designed to repair and restore heart function following myocardial injury.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CardiolRx TARGET CardiolRx Cardiol Therapeutics Inc. phase 3 Exosome therapy
Topical lyophilized exosomes application Topical lyophilized exosomes application Instituto de Oftalmología Fundación Conde de Valenciana marketed Exosome therapy
ExoFlo ExoFlo Direct Biologics, LLC phase 3 Exosome therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Exosome therapy class)

  1. Cardiol Therapeutics Inc. · 1 drug in this class
  2. Direct Biologics, LLC · 1 drug in this class
  3. Instituto de Oftalmología Fundación Conde de Valenciana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CardiolRx — Competitive Intelligence Brief. https://druglandscape.com/ci/cardiolrx. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: